Related Experiment Video

Updated: Jul 29, 2026

Pluripotent Stem Cell Derived Cardiac Cells for Myocardial Repair
06:37

Pluripotent Stem Cell Derived Cardiac Cells for Myocardial Repair

Published on: February 3, 2017

Plasma insulin-like growth factor-1 elevated in mild-to-moderate but not severe heart failure

M K Al-Obaidi1, J K Hon, P J Stubbs

  • 1National Heart and Lung Institute, Department of Cardiology, Imperial College School of Medicine, London, UK. m.al-obaidi@rbh.nthames.nhs.uk

American Heart Journal
|November 22, 2001
PubMed

Insights

Insulin-like growth factor 1 (IGF-1) levels are higher in heart failure patients, particularly those with mild symptoms. Higher IGF-1 correlates with better heart function, suggesting a role in compensated heart failure.

Area of Science:

  • Cardiology
  • Endocrinology
  • Biochemistry

Background:

  • Insulin-like growth factor 1 (IGF-1) is known to promote beneficial cardiac remodeling in heart failure.
  • The relationship between plasma IGF-1 levels and the varying severity of heart failure in patients has not been previously established.

Purpose of the Study:

  • To investigate the association between plasma IGF-1 levels and the clinical status of patients with heart failure.
  • To explore the correlation between IGF-1 levels and objective measures of cardiac function.

Main Methods:

  • Plasma samples were analyzed for IGF-1 levels in 24 heart failure patients and 21 controls.
  • Heart failure severity was assessed using the New York Heart Association (NYHA) classification.
  • Left ventricular fractional shortening (FS), a measure of ventricular performance, was determined via echocardiography.

Main Results:

  • Patients with heart failure exhibited higher mean IGF-1 levels compared to control subjects (20.2 vs. 14.1 mU/L).
  • Elevated IGF-1 levels were specifically observed in patients with mild-to-moderate heart failure (NYHA classes I and II), but not in those with severe symptoms (NYHA classes III and IV).
  • A significant positive correlation was found between IGF-1 levels and left ventricular fractional shortening (r = 0.58, P = .003), independent of confounders.

Conclusions:

  • Plasma IGF-1 levels vary significantly depending on the severity of heart failure.
  • IGF-1 may play a crucial role in maintaining cardiac function in compensated heart failure states.
Abstract

More Related Videos

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction03:42

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction

Published on: March 29, 2024

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.